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a b s t r a c t
Aberrant regulation in oxidative stress, ﬁbrogenesis, and the epithelial–mesenchymal transition (EMT) in renal
cells under hyperglycemic conditions contributes signiﬁcantly to the onset and progression of diabetic
nephropathy. The mechanisms underlying these hyperglycemia-induced dysregulations, however, have not
been clearly elucidated. Herein, we report that aldose reductase is capable of regulating the expression of miR-
200a-3p/141-3p negatively in renal mesangial cells. MiR-200a-3p/141-3p, in turn, act to target Keap1, Tgfβ2,
ﬁbronectin, and Zeb2 directly and regulate Tgfβ1 and Nrf2 indirectly under high-glucose conditions, resulting in
profound dysregulations in Keap1–Nrf2, Tgfβ1/2, and Zeb1/2 signaling. In vivo in streptozotocin-induced
diabetic mice, we found that aldose reductase deﬁciency caused signiﬁcant elevations in miR-200a-3p/141-3p
in the renal cortex, which were accompanied by a signiﬁcant downregulation of Keap1, Tgfβ1/2, and ﬁbronectin
but signiﬁcant upregulation of Nrf2. Moreover, in vivo administration of inhibitors of miR-200a-3p in diabetic
animals signiﬁcantly exacerbated cortical and glomerular ﬁbrogenesis and increased urinary albumin excretion,
tightly linking dysregulated miR-200a-3p with the development of diabetic nephropathy. Collectively, our
results reveal a novel mechanism whereby hyperglycemia induces aldose reductase to regulate renal
expression of miR-200a-3p/141-3p to coordinately control hyperglycemia-induced renal oxidative stress,
ﬁbrogenesis, and the EMT. Our novel ﬁndings also suggest that inhibition of aldose reductase and in vivo renal
cortical restoration of miR-200a-3p/141-3p or their combination are very promising avenues for the
development of therapeutic strategies or drugs against diabetic nephropathy.
& 2013 The Authors. Published by Elsevier Inc.
Diabetic kidney disease, or diabetic nephropathy (DN), is
morphologically characterized by excessive deposition of extracellular
matrix (ECM) with mesangial expansion, thickening of glomerular and
tubular basement membranes, podocyte effacement, and tubulointer-
stitial ﬁbrosis. Mechanistically, the development of DN has been
associated with overactivation of the polyol pathway, overﬂux of the
hexosamine pathway, marked alterations in intraglomerular hemody-
namics, generation of advanced glycation products, activation of
protein kinase C (PKC)/transforming growth factor-β (Tgfβ) signaling,
overproduction of reactive oxygen species (ROS), etc. [1–6].
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Aldose reductase (EC 1.1.1.21, AR) is a member of the aldo-keto
reductase protein family. Being the ﬁrst and the rate-limiting
enzyme of the polyol pathway, AR is known to play crucial roles
in the development of a variety of diabetic complications [7,8]. The
association of AR with the development of DN has recently been
unequivocally demonstrated by us, utilizing Ar-knockout mice [9].
Interestingly, we showed that Ar deﬁciency ameliorated the
development of DN in diabetic mice, predominantly by attenuat-
ing PKC and Tgfβ-induced ﬁbrogenesis. Moreover, we also showed
that Ar deﬁciency appeared to ameliorate diabetes-induced deple-
tion of glutathione in the renal cortex. However, the mechanisms
through which AR mediates renal cortical Tgfβ and antioxidant
defense signaling remained to be further investigated.
MicroRNAs (miRNAs) are small noncoding RNAs that are
emerging as key regulators in the cellular signaling networks
[10,11]. The miR-200 miRNA family was initially thought to have
ﬁve members, namely miR-200a, miR-141, miR-200b, miR-200c,
and miR-429 [12]. According to the newly released miRBase
(http://www.mirbase.org, release 19), however, in mice the ﬁve
miR-200 genes probably each encode a 3p sequence and a 5p
sequence (Supplementary Fig. S1). As such, human or mouse miR-
200 family miRNAs reported in almost all previous publications
actually represented exclusively the 3p sequences (miR-200-3p’s).
It is well established that miR-200-3p’s play important roles in
the development of many types of cancers by regulating cell
differentiation, proliferation, invasion, migration, etc. Moreover,
these miRNAs were also found to be involved in insulin signaling
[13], antioxidant defense [11,14–16], and ﬁbrogenesis [5,17–19].
MiR-200a-3p/141-3p, in particular, were shown to target p38α and
modulate the oxidative stress response in ovarian cancer cells [14].
In breast and ovarian cancer cells, miR-200a-3p/141-3p were also
found to interact with the 3′-untranslated region (3′UTR) of the
mRNA of Kelch-like ECH-associated protein-1 (Keap1), a negative
regulator of nuclear factor erythroid 2 p45-related factor-2 (Nrf2),
causing dysregulation of Nrf2-mediated antioxidant defense in
cancer cells [15,20]. Additionally, miR-200-3p’s were reported to
be transcriptionally regulated by Tgfβ1/2 [17,18,21–23]. Conver-
sely, the activin receptor type 2B (ACVR2B), a member of the
Tgfβ pathway, was identiﬁed as a single common target gene
for miR-192/194/215 and miR-141-3p/200c-3p [24]. Indeed, in
nephroblastomas these miRNAs were shown to be signiﬁcantly
downregulated, which was associated with an upregulation in
ACVR2B mRNA. In rat proximal tubule epithelial NRK52E cells,
miR-200a-3p/141-3p were also shown to repress the expression of
Tgfβ2 via direct interaction with its 3′UTR [23]. Prompted by these
and other ﬁndings, we hypothesized that in the renal cortex, AR
might regulate the expression of miR-200-3p’s to control antiox-
idant defense and Tgfβ1/2 and Zeb1/2 signaling. This study
examined this hypothesis in cultured renal mesangial cells and
in renal cortical tissues from diabetic mice that were either wild-
type or deﬁcient for Ar owing to genetic manipulations [9].
Methods
Plasmids and lentiviruses
Twelve chimeric 3′UTR–luciferase reporter plasmids for Keap1,
Tgfβ2, and ﬁbronectin (Fn) and plasmids overexpressing miR-200a-
3p/141-3p (pmiR-200a and pmiR-141) were prepared as described in
the supplementary material andmethods and Supplementary Fig. S2.
p3AREs-luc, which is a human aldo-keto reductase Akr7a3 gene
promoter–luciferase reporter containing three antioxidant-response
elements (AREs) was as described previously [25]. p3TP-lux, which is
a Tgfβ-inducible reporter [26], was a kind gift from Dr. Hongrui Wang
of Xiamen University. Lentiviruses carrying short hairpin RNAs
(shRNAs) for Ar and an Ar-overexpressing pFlag-mAR and its control
were prepared as described previously [27,28].
Cell culture, transient transfection, and treatments
The mouse mesangial SV40-Mes13 (Mes13) cells were
purchased from the ATCC (Manassas, VA, USA). Cells were nor-
mally cultured in a 3:1 mixture (v/v) of Dulbecco's modiﬁed Eagle
medium (DMEM; 25 mM glucose) and Ham’s F-12 (GIBCO, Grand
Island, NY, USA), which resulted in a medium containing 5% fetal
bovine serum (GIBCO) and 17.7 mM glucose, unless indicated
otherwise. For AR inhibition, cells were treated with 100 μM
zopolrestat, an inhibitor of AR (ARI), provided by Pﬁzer Global
Research and Development (Groton, CT, USA) as a gift. Alterna-
tively, cells were infected with lentiviruses containing shRNAs
against Ar [28]. Plasmid DNA transfection was performed with
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. For miR-200a-3p
inhibition in vitro, antogomiR-200a-3p and its control were
purchased from RiboBio Co., Ltd. (Cat. No. miR20000519-1-5;
Guangzhou, China) and used as instructed.
Western blot analyses
Protein samples were extracted from cultured cells or kidney
tissues with the radioimmune precipitation assay lysis buffer.
Western blot analysis was performed according to conventional
protocols using antibodies described in Supplementary Table S5
and a Supersignal chemiluminescent substrate kit (Millipore,
Billerica, MA, USA).
ROS production and GSH depletion in Mes13 cells
Cells were seeded on six-well plates at the density of 5105/
well and in triplicate and incubated in a mixture of DMEM and
Ham’s F-12 medium (3:1; 17.7 mM glucose). For Ar overexpression,
cells were transfected with pFlag-mAR or pFlag-mAR plus pmiR-
200a. For AR inhibition, cells were incubated in fresh medium
containing 100 μM ARI or ARI þ antogomiR-200a-3p. After the
treatments, the cells were washed twice and resuspended in
phosphate-buffered saline (PBS), and then 2′,7′-dichlorodihydro-
ﬂuorescin diacetate (Sigma–Aldrich) was added to the resuspended
cells at a ﬁnal concentration of 10 mmol/L. Fluorescence was mea-
sured at 485/530 nm in a microplate reader (POLARstar Omega;
BMG Labtech, Ortenberg, Germany). Intracellular GSH was measured
using a commercial kit from Jiancheng Bioengineering Institute
(Nanjing, China), following the manufacturer’s instructions.
Animals and diabetes induction
Three genotype groups of male C57BL/6 mice, which included
the wild-type mice (WT, Arþ /þ), the Ar-knockout mice (KO, Ar /),
and the bitransgenic line of mice (BT; KspArþ /::Ar/), were
prepared and the induction of diabetes was performed with
streptozotocin (STZ) injection as described previously [9]. All animal
experiments were carried out in accordance with the guidelines of
the Xiamen University Institutional Committee for the Care and Use
of Laboratory Animals.
In vivo knockdown of miR-200a-3p by lentivirus-mediated gene
silencing
One pair of oligonucleotides (5′-tATTGTCTGTCTGGTAAC-
GATGTttcaagagaACATCGTTACCAGACAGTGTTAttttttc-3′ and 5′-tcg
aga;aaaaaTAACACTGTCTGGTAACGATGTtctcttgaaACATCGTTACCAGA-
CAGACAATa-3′; the uppercase nucleotides indicate the stem of the
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hairpin and the italicized nucleotides indicate the target sequence)
was designed to contain a shRNA gene cassette against mmu-miR-
200a-3p. Another pair of scrambled oligonucleotides (5′-tAC-
TACCGTTGTTATAGGTGttcaagagaCACCTATAACAACGGTAGTttttttc-3′
and 5′-tcgagaaaaaaACTACCGTTGTTATAGGTGtctcttgaaCACCTATAA-
CAACGGTAGTa-3′) was designed to serve as a negative control
gene cassette. These two pairs of primers were chemically synthesized
by Sangon Biotech (Shanghai, China). Annealed pairs of oligonucleo-
tides were digested with HpaI and XhoI and inserted into the pLL3.7-
GFP vector (CPG Biotech Co., Ltd., Shanghai, China), generating
pLV-anti-miR-ctrl and pLV-anti-miR-200a-3p, respectively. For lenti-
virus preparation, HEK-293T cells (1.2107) were plated in 15-cm
plates and cultured overnight in DMEM containing 10% fetal bovine
serum. Cells were subsequently transfected with a mixture of four
plasmids (20 mg pLV-anti-miR-ctrl or pLV-anti-miR-200a-3p, 10 mg
VSVG, 10 mg RSV-REV, 10 mg pMDL/pRRE; VSVG, RSV-REV, and
pMDL/pRRE were as described previously [29,30] and available from
the National Gene Vector Biorepository, Indianapolis, IN, USA). Viral
particles for control lentiviruses (LV-anti-miR-ctrl) or lentiviruses
carrying shRNA for miR-200a-3p (LV-anti-miR-200a-3p) were
obtained by ﬁltering the supernatants collected at 48 and 72 h after
the transfection with a 0.45-μm ﬁlter (Millipore) and centrifugation at
90,000g for 90 min. Pelleted viral particles were resuspended and
diluted 20-fold in PBS and stored at 80 1C until use.
For in vivo inhibition of miR-200a-3p, 9-week-old male WT, KO,
and BT mice were injected with STZ to induce diabetes as described.
Fig. 1. Effects of AR on antioxidant defense- and ﬁbrogenesis-related genes in Mes13 cells. For Ar overexpression, Mes13 cells were transfected with pFlag-mAR. For AR
inhibition, Mes13 cells were treated with 100 μM ARI or infected with lentiviruses containing shRNA for Ar. 24 h after treatment, the cells were harvested for analyses. Data
are expressed as the mean 7 SEM, n ¼ 3. np o 0.05; nnp o 0.01; nnnp o 0.001; compared to either the pFlag-CMV2-transfected cells or vehicle-treated cells. (A) Effects of
Ar overexpression or inhibition on the mRNA expression of Keap1, Nrf2, Nqo1, Gclc, Gsta1, and Zeb1/2. (B) Effects of Ar overexpression or inhibition on the protein expression
of Keap1, Nrf2, and Zeb1/2. (C) Effects of Ar overexpression or inhibition on the mRNA expression of Tgfβ1, Tgfβ2, Col4, and Fn. (D) Inhibition of AR by ARI treatment or by
lentivirus-mediated Ar knockdown suppressed the protein expression of Tgfβ2 and Fn. LV-CK, control lentiviruses; LV-shAR-1 and LV-shAR-2, lentiviruses carrying shRNAs
for Ar.
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Four weeks later, mice in each genotype group were randomly divided
into two subgroups and were injected in the tail vein with 5107
transducing units of either control lentiviruses or lentiviruses carrying
shRNA for miR-200a-3p (LV-anti-miR-ctrl or LV-anti-miR-200a-3p)
once every 2 weeks for 1 month. Urine was collected from 17-week-
old mice that were placed in metabolic cages for 24 h with free access
to food and water. Urine volume was measured and the urine samples
were centrifuged at 2000g for 20 min. The supernatants were stored
at 80 1C before use. Urine albumin was measured using an ELISA kit
from ADL (Beijing, China). Immediately after the collection of urine,
17-week-old mice were sacriﬁced and both kidneys were rapidly
dissected and weighed (wet weight) before kidneys were snap-frozen
and stored at 80 1C or put in 10% buffered formalin (v/v) before
being embedded in parafﬁn. Kidney sections at 5 mm thickness were
stained with periodic acid–Schiff (PAS) and examined under a light
microscope.
RNA extraction and real-time quantitative RT-PCR (qPCR) analysis
of mRNAs and miRNAs
Total RNA was isolated from the cultured cells and kidney tissues
using TRIzol reagent (Invitrogen) according to the manufacturer’s
protocols. For mRNA quantiﬁcation, reverse transcription was per-
formed with TRIzol-extracted total RNA using a ReverTra Ace-α kit as
instructed (Toyobo, Tokyo, Japan). qPCR was performed using the SYBR
Green Real-Time PCR Master Mix (Toyobo) and the StepOne Real-Time
qPCR system (Applied Biosystems, Foster City, CA, USA) using the
primer pairs listed in Supplementary Table S3 and according to the
manufacturer’s protocols. The levels of mRNA expression were cali-
brated with the expression of 18S rRNA.
For miRNAs, qPCR was performed with the stem–loop primers
as described previously [31] using the miRNA-speciﬁc reverse
transcription primers, the universal primer and the miRNA-
speciﬁc reverse LNA primers are described in Supplementary
Table S4. U6 RNA served as an endogenous control.
Luciferase reporter assays
Luciferase reporter activities were determined using a Lucifer-
ase Reporter Gene Assay System (Promega, Madison, WI, USA) as
instructed. For all luciferase assays, β-galactosidase activities were
determined to calibrate for the transfection efﬁciency. The cali-
brated value for a proper control was used to normalize all other
values to obtain the normalized relative luciferase units represent-
ing the activities of 3′UTR-containing luciferase reporters.
Bioinformatics and statistical analyses
Mature and pre-miRNA sequences were based on miRBase.
MiRNA target predictions were performed with the miRanda
(www.microrna.org) and TargetScan (www.targetscan.org) algo-
rithms or by manual searches for MREs based on the seed
sequences. Data were expressed as the means 7 SEM. One-way
ANOVA or repeated-measures two-way ANOVA with Bonferroni’s
posttest were used for multiple comparisons and the Student t test
(two-tailed) for pair-wise comparisons.
Results
The expression of Ar was tightly linked to the expression of major
genes associated with antioxidant defense, ﬁbrogenesis, and EMT in
cultured Mes13 cells
To determine how changes in AR activity might affect the
expression of genes involved in antioxidant defense, ﬁbrogenesis,
and EMT, we performed transfections with an Ar-overexpressing
plasmid (pFlag-mAR) [27] to increase Ar expression in Mes13 cells.
Alternatively, we inhibited AR by treating the cells with the ARI
zopolrestat at the concentration of 100 μM or infecting the cells
with lentiviruses containing shRNAs for Ar [28]. As shown in
Figs. 1A and C, overexpression of Ar strongly upregulated, but
inhibition of AR greatly downregulated, the mRNA expression of
Keap1, Zeb1/2, Tgfβ1/2, collagen IV (Col4), and Fn. In contrast,
overexpression of Ar downregulated but inhibition of AR upregu-
lated the mRNA expression of Nrf2 and Nrf2-targets including
NADH quinone oxidoreductase (Nqo1), glutamate–cysteine ligase
catalytic subunit (Gclc), and glutathione S-transferase α-1 (Gsta1)
(Fig. 1A), whereas neither overexpression of Ar nor inhibition of AR
signiﬁcantly affected the expression of cyclin-dependent kinase 4
(Cdk4), Cdk6, and p27Kip1 (Supplementary Fig. S3). Furthermore,
the protein levels of Keap1, Nrf2, Tgfβ2, and Fn were signiﬁcantly
altered accordingly (Figs. 1B and D). To further demonstrate the
effects of AR on the transcriptional activity mediated by Nrf2 or
Tgfβ1/2, we performed transfection studies with an Nrf2-inducible
p3AREs-luc [25] or a Tgfβ-inducible p3TP-lux luciferase reporter
[26] in Mes13 cells that were cotransfected with pFlag-mAR or
infected with lentiviruses containing shRNAs for Ar. As shown in
Fig. 4A, Ar overexpression suppressed but AR inhibition enhanced
Nrf2 signaling. In contrast, Ar overexpression enhanced but AR
inhibition suppressed Tgfβ signaling. Together these results indi-
cate that in Mes13 cells, AR mediates renal antioxidant defense,
ﬁbrogenesis, and EMT predominantly by modulating Keap1–Nrf2,
Tgfβ1/2, and Zeb1/2 signaling.
High glucose exposure or overexpression of Ar signiﬁcantly
downregulated, whereas inhibition of AR signiﬁcantly upregulated,
the expression of miR-200-3p’s in Mes13 cells
In a recent study, we observed that Ar deﬁciency was asso-
ciated with a signiﬁcant elevation in the expression of miR-200b-
3p in the renal medulla of C57BL/6 mice [31]. We therefore
reasoned that AR might control the expression of miR-200-3p’s
in other regions of the kidney as well. To determine whether the
expression of miR-200-3p’s is regulated by AR, we transfected
Mes13 cells with pFlag-mAR or treated the cells with 100 μM ARI
for 24 h. Interestingly, overexpression of Ar signiﬁcantly down-
regulated the expression of miR-200a-3p/141-3p (24% for miR-
200a-3p, po0.01, and 33% for miR-141-3p, po0.05, Fig. 2A).
Moreover, in comparison with 5.6 mM glucose-exposed cells that
were osmotically compensated for with mannitol, the exposure of
Mes13 cells to 16.7 or 30 mM glucose caused a steep down-
regulation of miR-200a-3p within 1–2 h, whereas ARI treatment
effectively diminished high-glucose-induced suppression of miR-
200a-3p (Fig. 2B). In contrast to Ar overexpression, inhibition of AR
caused a very signiﬁcant upregulation in the expression of all
members of miR-200-3p (Fig. 2A). Together these data establish
that high glucose or high glucose-responsive AR is capable of
regulating the expression of miR-200-3p’s and that miR-200-3p’s
are highly glucose-responsive in renal mesangial cells.
MiR-200a-3p/141-3p controlled renal Keap1–Nrf2, Tgfβ1/2,
and Zeb1/2 signaling directly or indirectly
Recent studies showed that in breast cancer cells, miR-200a-
3p/141-3p regulates the expression of Keap1 directly, thereby
inﬂuencing cellular redox homeostasis in cancer cells [15,20].
Moreover, miR-200a-3p/141-3p were shown to be able to target
Tgfβ2 to control renal ﬁbrosis in rat proximal tubule epithelial cells
[23]. These studies and our results as shown in Figs. 1, 2, and 4A
prompted us to hypothesize that AR might regulate miR-200a-3p/
141-3p to modulate Keap1–Nrf2, Tgfβ1/2, and Zeb1/2 signaling in
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the renal cortex. To test this hypothesis, we overexpressed miR-
200a-3p/141-3p in Mes13 cells or treated cells with a miR-200a-3p
antagonist. In cells whose miR-200a-3p/141-3p were increased by
approximately threefold (Fig. 3A), increased expression of miR-
200a-3p/141-3p caused signiﬁcant downregulation of Keap1,
Tgfβ1/2, Col4, Fn, and Zeb2, but signiﬁcant upregulation of Nrf2
and E-cad mRNA expression (Fig. 3C), whereas inhibition of miR-
200a-3p caused a signiﬁcant upregulation in the mRNA expression
of Keap1, Tgfβ1/2, Col4, and Fn but signiﬁcant downregulation of
Nrf2 (Fig. 3B). Correspondingly, the protein expression of Keap1,
Nrf2, Col4, Fn, and Tgfβ2 was signiﬁcantly altered upon over-
expression or inhibition of miR-200a-3p (Fig. 3D). To further
demonstrate the impact of miR-200a-3p/141-3p on the transcrip-
tional activity mediated by Nrf2 or Tgfβ1/2, we transfected Mes13
cells with pFlag-mAR in the presence of luciferase reporter
p3AREs-luc or p3TP-lux. We found that overexpression of miR-
200a-3p/141-3p signiﬁcantly enhanced Nrf2 signaling but attenu-
ated Tgfβ signaling (Fig. 4B). Together these results suggest that
miR-200a-3p/141-3p are crucial regulators of Keap1–Nrf2, Tgfβ1/2,
and Zeb1/2 signaling in the renal mesangial cells.
MiR-200a-3p/141-3p regulate the expression of Keap1, Tgfβ2, and Fn
directly and posttranscriptionally
We performed bioinformatics analyses and found that miR-
200a-3p/141-3p might be able to target mouse Keap1, Tgfβ2, and Fn
posttranscriptionally. Two MREs for miR-200a-3p/141-3p were
found on the 3′UTR of Keap1, three MREs were found on the
3′UTR of Tgfβ2, and two MREs were found on the 3′UTR of Fn
(Supplementary Fig. S2). To demonstrate that miR-200a-3p/141-3p
target Keap1, Tgfβ2, and Fn directly, we created four luciferase
reporters, i.e., the full-length 3′UTR, a truncated 3′UTR that did not
contain any putative MREs, a truncated 3′UTR that contained a
single wild-type MRE, and a truncated 3′UTR that contained a
single mutated MRE, for each of the three putative target genes
(Supplementary Fig. S2). Cotransfection studies of plasmids over-
expressing miR-200a-3p or miR-141-3p with either one of the
three sets of 3′UTR–luciferase reporters conﬁrmed that miR-200a-
3p/141-3p indeed repressed Keap1, Tgfβ2, and Fn by interacting
with the corresponding putative MRE on the 3′UTR. For instance,
in Mes13 cells cotransfected with the full-length wild-type 3′UTR
of Keap1, increased expression of miR-200a-3p caused 54%
reduction in the luciferase reporter activity, but in cells cotrans-
fected with the truncated and non-MRE-containing 3′UTR, this
silencing effect was absent (Fig., 4C). Meanwhile, in cells cotrans-
fected with the 3′UTR of Keap1 containing mutated MRE, the
silencing effect of miR-200a-3p was completely abolished. More-
over, similar results were observed for miR-141-3p (Fig. 4C) and
for the Tgfβ2 3′UTR and Fn 3′UTR (Figs. 4D and 4E). Together these
results suggest that miR-200a-3p/141-3p repress Keap1, Tgfβ2, and
Fn directly and via miR-200-3p-mediated gene silencing in mouse
renal mesangial cells.
Reintroduction of miR-200a-3p signiﬁcantly suppressed AR-induced
overproduction of ROS and depletion of GSH
To determine the effects of AR and miR-200a-3p on ROS produc-
tion and GSH depletion, we assayed the levels of ROS and GSH in
cultured Mes13 cells (Fig. 5). As expected, overexpression of Ar
Fig. 2. Effects of high glucose or Ar overexpression or AR inhibition on the expression of miR-200-3p’s in Mes13 cells. Data are expressed as the mean 7 SEM, n ¼ 3.
np o 0.05; nnp o 0.01; nnnp o 0.001; compared to either the pFlag-CMV2-transfected cells or the vehicle-treated cells. (A) Effects of Ar overexpression or inhibition on the
expression of miR-200-3p’s in Mes13 cells. Cells were seeded on six-well plates at the density of 5105/well and in triplicate and incubated in high-glucose DMEM and
Ham’s F-12 medium (3:1) containing 17.7 mM glucose. For Ar overexpression, cells were transfected with pFlag-mAR. For AR inhibition, cells were replaced with fresh
medium containing 100 μM ARI. 24 h after treatment, the cells were harvested for analyses. (B) Time course of effects of various concentrations of glucose on the expression
of miR-200a-3p in Mes13 cells. All cells were preconditioned on six-well plates at the density of 5105/well and in triplicate and incubated in low-glucose DMEM and
Ham’s F-12 medium (3:1) with glucose supplemented to a ﬁnal concentration of 5.6 mM for 24 h. Subsequently, cells were divided into ﬁve groups and glucose treatments
were started by replacing the old medium with fresh medium containing 5.6 mM glucose, 5.6 mM glucose þ 11.1 mM mannitol, 5.6 mM glucose þ 24.4 mM mannitol,
16.7 mM glucose, or 30 mM glucose, respectively. Mannitol was used to compensate for the high glucose osmolarity.
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signiﬁcantly increased but inhibition of AR signiﬁcantly decreased
the ROS production (Fig. 5A). In contrast, overexpression of Ar
signiﬁcantly decreased but inhibition of AR signiﬁcantly increased
intracellular GSH (Fig. 5B). Moreover, cotransfection of pmiR-200a
signiﬁcantly reduced the ROS level in Ar-overexpressing cells
(pFlag-mARþpmiR-200a) but cotransfection of antagomiR-200a-3p
signiﬁcantly increased the ROS level in ARI-treated cells (ARI þ
antagomiR-200a-3p) (Fig. 5A). Meanwhile, cotransfection of pmiR-
200a signiﬁcantly ameliorated GSH depletion in Ar-overexpressing
cells (pFlag-mARþpmiR-200a) but cotransfection of antagomiR-200a-
3p signiﬁcantly exacerbated GSH depletion in ARI-treated cells
(ARIþantagomiR-200a-3p) (Fig. 5B). These results clearly demonstrate
that the AR-miR-200-3p–Keap1–Nrf2 axis plays crucial roles in anti-
oxidant defense in Mes13 cells.
Increased miR-200a-3p/141-3p expression was associated with
downregulated Keap1, Tgfβ1/2, Zeb1/2, and Fn but upregulated Nrf2
in the renal cortical tissues of Ar-deﬁcient diabetic mice
To determine whether AR-mediated alterations in the expression
of miR-200a-3p/141-3p and the antioxidant defense, ﬁbrogenesis,
and EMT-related genes observed in cultured mesangial cells are
applicable to renal cortical tissues in vivo, we examined the
expression of miR-200a-3p/141-3p, Keap1, Nrf2, Tgfβ1/2, Zeb1/2,
Fig. 3. MiR-200a-3p/141-3p regulates Keap1–Nrf2, Tgfβ1/2, and Zeb2 signaling in Mes13 cells. Cells were transfected with pmiR-200a or pmiR-141 or antagomiR’s and
incubated for 24 h. Data are expressed as the mean 7 SEM, n ¼ 3. np o 0.05; nnp o 0.01; nnnp o 0.001; compared to either the pFlag-CMV2-transfected cells or the
antagomiR-ctrl-transfected cells. (A) Transfection with pmiR-200a or pmiR-141 caused increased expression of miR-200a-3p or miR-141-3p in Mes13 cells. (B) Inhibition of
miR-200a-3p elevated the mRNA expression of Keap1, Tgfβ1/2, Col4, and Fn but suppressed the mRNA expression of Nrf2. (C) Overexpression of miR-200a-3p/141-3p
suppressed the mRNA expression of Keap1, Tgfβ1/2, Col4, Fn, and Zeb2 but elevated the mRNA expression of Nrf2 and E-cad. (D) Overexpression of miR-200a-3p suppressed
the protein expression of Keap1, Col4, Fn, and Tgfβ2 but elevated Nrf2, whereas inhibition of miR-200a-3p elevated the protein expression of Keap1, Col4, Fn, and Tgfβ2 but
suppressed Nrf2, as determined by Western blots.
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and Fn in renal cortical tissues from three groups of diabetic C57BL/6
mice, namely the WT (Arþ /þ), the Ar KO (Ar /), and the BT
(KspArþ /::Ar /) mice [9]. The BT mice differ from the KO mice
only in that, in addition to the Ar-knockout allele, the BTmice carry a
knock-in transgene (KspArþ /) in which a mouse kidney-speciﬁc
cadherin gene promoter drives the expression of Ar in a collecting
tubule epithelial cell-speciﬁc manner [9]. Remarkably, in comparison
with that of the diabetic WT mice, renal cortical expression of
miR-200a-3p/141-3p was signiﬁcantly elevated in both the diabetic
KO and the diabetic BT mice (Fig. 6A). Similarly, Ar deﬁciency was
also shown to signiﬁcantly elevate miR-200a-3p in the renal cortex
of 11-week-old db/db mice (Supplementary Fig. S4). Furthermore,
Fig. 4. MiR-200a-3p/141-3p regulates Keap1–Nrf2 and Tgfβ1/2 signaling through miRNA-mediated posttranscriptional silencing. Mes13 cells were cotransfected with either
pmiR-200a or pmiR-141, a luciferase reporter plasmid, and a β-galactosidase-overexpressing plasmid at a ratio of 4:3:1. 24 h after transfection, the cells were harvested for
analyses. The luciferase reporter plasmids included either p3AREs-luc [25] or p3TP-lux [26] or one of the plasmids containing the 3′UTR sequence derived from Keap1 or
Tgfβ2 or Fn as depicted in Supplementary Fig. S2. The β-galactosidase activity was used to calibrate for the transfection efﬁciency. Data are expressed as the mean 7 SEM,
n ¼ 3. NS, not signiﬁcant; np o 0.05; nnp o 0.01; nnnp o 0.001; all compared to an appropriate control treatment. (A) Overexpression of miR-200a-3p/141-3p stimulates
Nrf2 transcriptional activity but suppresses Tgfβ transcriptional activity as determined by luciferase activity assay. (B) MiR-200a-3p/141-3p regulates Keap1 by interacting
with the putative MRE on the Keap1 3′UTR. (C) MiR-200a-3p/141-3p regulates Tgfβ2 by interacting with the putative MRE on the Tgfβ2 3′UTR. (D) MiR-200a-3p/141-3p
regulates Fn by interacting with the putative MRE on the Fn 3′UTR. RLU, relative luciferase unit.
Fig. 5. Effects of Ar/miR-200a-3p overexpression and inhibition on (A) ROS production and (B) GSH depletion in Mes13 cells. Mes13 cells were prepared and treated as
described under Methods. Cells were harvested for analyses at the time points indicated. Data are expressed as the mean 7 SEM, n ¼ 3. np o 0.05, nnp o 0.01, nnnp o 0.001,
comparing the vehicle-treated cells and the ARI-treated cells; ##p o 0.01, ###p o 0.001, comparing the pFlag-CMV2-treated cells and the pFlag-mAR-treated cells.
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with the elevations in miR-200a-3p/141-3p, the mRNA and protein
expression of Keap1, Tgfβ1/2, Zeb1/2, Fn, and Col4 was greatly
reduced, whereas Nrf2 was greatly increased in the STZ-diabetic
mice (Figs. 6B and 6C), suggesting greatly enhanced Nrf2-mediated
antioxidant defense and signiﬁcantly attenuated Tgfβ-dependent
renal ﬁbrogenesis. In mice that were injected with 0.1 mM citrate
buffer, which served as the nondiabetic controls, AR did not
signiﬁcantly affect the expression of miR-200a-3p/141-3p or the
mRNA expression of Keap1, Nrf2, Tgfβ1/2, Fn, and Zeb1/2 in the renal
cortex (Supplementary Fig. S5). Together these results indicate that
Ar deﬁciency stimulates the expression of miR-200a-3p/141-3p in
diabetic mice to enhance Nrf2-mediated antioxidant defense and to
suppress Tgfβ-dependent renal ﬁbrogenesis and EMT in a coordi-
nated manner.
In vivo administration of lentiviruses carrying shRNAs against
miR-200a-3p exacerbated cortical and glomerular ﬁbrogenesis
and urinary albumin excretion in diabetic mice
To further ascertain the regulatory roles of miR-200a-3p
in vivo, we treated three genotype groups of diabetic mice with
lentiviruses carrying a control shRNA (LV-anti-miR-ctrl) or a
shRNA against miR-200a-3p (LV-anti-miR-200a-3p). In compari-
son with the 17-week-old mice that were diabetic for 8 weeks and
received LV-anti-miR-ctrl injection, the 17-week-old diabetic mice
that received LV-anti-miR-200a-3p once every 2 weeks for
1 month showed a signiﬁcant suppression of renal cortical
expression of miR-200a-3p (Fig. 7A). Of note is that the miR-
200a-3p levels in the Ar-deﬁcient (KO and BT) mice that received
LV-anti-miR-200a-3p still appeared to be slightly higher than
those of the WT mice that received LV-anti-miR-200a-3p, pre-
sumably because Ar deﬁciency was capable of stimulating miR-
200a-3p biosynthesis. In comparison with that of the diabetic mice
that received LV-anti-miR-ctrl, renal cortical expression of Tgfβ2
and Keap1 in diabetic mice of the same genotype that received
LV-anti-miR-200a-3p appeared to be largely increased, but that of
Nrf2 was greatly reduced (Fig. 7B). With the suppression of miR-
200a-3p, signiﬁcant exacerbation of cortical and glomerular ﬁbro-
genesis was observed in all diabetic mice that received LV-anti-
miR-200a-3p, irrespective of the activity of AR (Fig. 7C). More
interestingly, in vivo suppression of miR-200a-3p signiﬁcantly
elevated urinary albumin excretion in all diabetic mice that
received LV-anti-miR-200a-3p (Fig. 7D). In Ar-deﬁcient KO and
BT mice that received LV-anti-miR-200a-3p, however, the urinary
albumin excretion was still lower than that of the WT mice that
received LV-anti-miR-200a-3p, indicating once again that AR
inhibition was beneﬁcial. Together these data further establish
the important regulatory role of miR-200a-3p in DN development
or progression in diabetic animals.
Discussion
In certain qPCR and Western blot analyses of this study, there
were cases in which the sample number was relatively low (n ¼ 3)
owing to the consideration of experimental handling. It is true that
low sample number might potentially limit the interpretation of
the statistical results. However, in our cases the data were often
repeatedly cross-examined by multiple techniques and/or multiple
models (e.g., qPCR mRNA analyses versus Western blots of
proteins, gain-of-function versus loss-of-function, in vitro versus
in vivo, pharmacological inhibitor versus shRNA-mediated gene
silencing, normoglycemia versus hyperglycemia, etc.). These see-
mingly reiterated experimental designs thus should help to dis-
sipate the potentially low force of the statistical tests associated
with low sample number.
We showed previously that genetic deﬁciency of Ar counter-
acted the development of DN in C57BL/6 mice in part by attenuat-
ing Tgfβ-dependent ﬁbrogenesis and hyperglycemia-induced
oxidative stress [9]. Traditionally, it was thought that renal
ﬁbrogenesis is largely due to sustained diacylglycerol-induced
activation of PKC–Tgfβ signaling [7,32]. In this study, we focused
on whether and how AR might regulate ﬁbrogenesis through
mechanisms other than PKC-induced Tgfβ activation. We found
Fig. 6. Upregulation of miR-200a-3p and miR-141-3p in the renal cortex of diabetic mice deﬁcient in Ar is linked with enhanced antioxidant defense and ameliorated renal
ﬁbrogenesis. WT, Arþ /þ; KO, Ar/; BT, KspArþ /::Ar / . RNA was extracted from the renal cortex of WT, KO, and BT mice that had been diabetic for 17 weeks. Data are
expressed as the mean 7 SEM, n ¼ 3. np o 0.05; nnp o 0.01; nnnp o 0.001; all compared to the diabetic WT mice. (A) MiR-200a-3p and miR-141-3p were signiﬁcantly
upregulated in renal cortex of diabetic mice deﬁcient in Ar (KO and BT). (B) Keap1, Tgfβ1/2, Fn, and Zeb1/2 mRNAs were signiﬁcantly decreased but Nrf2 mRNA was
signiﬁcantly increased in renal cortex of diabetic mice deﬁcient in Ar. (C) Keap1, Tgfβ2, Fn, and Zeb1/2 proteins were signiﬁcantly decreased but Nrf2 protein was signiﬁcantly
increased in renal cortex of diabetic mice deﬁcient in Ar.
J. Wei et al. / Free Radical Biology and Medicine 67 (2014) 91–10298
that in cultured Mes13 cells, Ar overexpression downregulated the
expression of miR-200-3p’s, whereas inhibition of AR by either ARI
or shRNA-mediated Ar knockdown caused signiﬁcant elevations in
the expression of miR-200-3p’s (Fig. 2). Importantly, we demon-
strated that increased miR-200a-3p/141-3p caused a signiﬁcant
downregulation in the expression of Tgfβ1/2, Col4, and Fn.
In contrast, inhibition of miR-200a-3p was linked to a signiﬁcant
upregulation in the expression of these four proﬁbrotic genes.
Moreover, miR-200a-3p/141-3p were shown to repress both Tgfβ2
and Fn directly by interacting with the MREs located on their
corresponding 3′UTR (Fig. 4). In Ar-deﬁcient mice that had become
diabetic for 17 weeks, the renal cortical expression of miR-200a-
3p/141-3p in diabetic KO and BT mice was greatly increased,
which was also associated with signiﬁcant downregulation in
the mRNA and protein expression of Tgfβ2 and Fn (Fig. 6). We
noticed that although Tgfβ1 is not a direct target of miR-200a-3p/
141-3p, its expression was often coregulated in the same direction
with that of Tgfβ2, which is consistent with previous observations
in rat tubule epithelial cells [23]. Furthermore, in vivo adminis-
tration of inhibitors against miR-200a-3p accelerated renal cortical
and glomerular ﬁbrogenesis and increased urinary albumin excre-
tion, indicating that miR-200a-3p negatively regulates the devel-
opment or progression of DN. Together these data indicate that in
renal mesangial cells and renal cortex of diabetic mice, AR is
capable of regulating the expression of miR-200a-3p/141-3p to
control Tgfβ1/2 activation. This AR–miR-200a-3p/141-3p–Tgfβ1/2
signaling cascade thus represents a novel posttranscriptional
mechanism whereby renal Tgfβ signaling and EMT and ﬁbrogen-
esis are linked to hyperglycemia-induced activation of the polyol
pathway via the epigenetic regulation of miR-200-3p’s.
Oxidative stress is central to the development of diabetic com-
plications [3,4,33,34], and hyperglycemia-induced overactivation of
AR/the polyol pathway in particular is one of the major routes
whereby oxidative stress occurs in tissue sites prone to diabetic
complications [35–37]. Although hyperglycemia is thought to induce
superoxide overproduction in the mitochondria [38], overactivation
of AR/the polyol pathway in the cytoplasm might contribute
signiﬁcantly to cellular redox imbalance as well [3,36]. Speciﬁcally,
overactivation of AR might lead to both increased ROS generation
and reduced capacity in antioxidant defense [35,36]. Recent data,
however, also suggested that the disruption of antioxidant defense
systems might be the major cause of AR-induced oxidative stress
[36]. Lines of evidence in support of this include: (1) in many types of
diabetic tissues, overactivation of AR/the polyol pathway was often
associated with glutathione depletion, which can be prevented or
reversed by AR inhibition [39–41]; (2) in many types of diabetic
tissues, overactivation of AR/the polyol pathway was often associated
downregulation of antioxidant defense enzymes including catalase,
superoxide dismutase, glutathione reductase, and glutathione per-
oxidase [42–44]; and (3) ablation of AR or inhibition of AR by ARIs
was associated with the simultaneous restoration of multiple anti-
oxidant defense enzymes [45]. Despite this, the mechanisms under-
lying the inverse correlation between AR expression and glutathione
depletion and the coregulation of multiple antioxidant enzymes by
Ar overexpression or inhibition were not clear. Recent studies have
shown that Nrf2 is an oxidative stress-responsive master transcrip-
tion factor for many antioxidant defense enzymes [34,46,47]. Our
current study, however, is the ﬁrst to show that AR regulates
miR-200a-3p/141-3p to posttranscriptionally control Keap1 to mod-
ulate Nrf2 signaling in renal cells, which provides a novel mechanism
for the disruption of antioxidant defense under diabetic conditions.
In this way, multiple Nrf2-regulated antioxidant defense enzymes are
coordinately controlled by an AR–miR-200a-3p/141-3p–Keap1–Nrf2
signaling cascade such that when AR is activated these antioxidant
Fig. 7. Inhibition of miR-200a-3p in diabetic mice exacerbated hyperglycemia-induced urinary albumin excretion and renal ﬁbrogenesis. The induction of diabetes and the
treatment with lentiviruses carrying shRNA against miR-200a-3p were as described under Methods. At the age of 17 weeks, urine samples were collected from the mice for
analyses of urinary albumin excretion. The mice were eventually sacriﬁced and renal tissues were dissected for protein expression analyses and renal histological analyses by
PAS staining. The six groups of mice were WT þ LV-anti-miR-ctrl, n ¼ 5; WT þ LV-anti-miR-200a-3p, n ¼ 4; KO þ LV-anti-miR-ctrl, n ¼ 5; KO þ LV-anti-miR-200a-3p, n ¼
5; BT þ LV-anti-miR-ctrl, n ¼ 4; and BT þ LV-anti-miR-200a-3p, n ¼ 5. Data are expressed as the mean 7 SEM. NS, not signiﬁcant; np o 0.05, nnp o 0.01, nnnp o 0.001,
compared to the LV-anti-miR-ctrl-treated diabetic mice of the same genotype; #p o 0.05, ##p o 0.01, compared to LV-anti-miR-200a-3p-treated diabetic WT mice. (A) The
renal cortical expression of miR-200a-3p in the kidneys of six groups of STZ-induced diabetic mice. (B) Typical Western blots demonstrating the protein expression of Keap1,
Nrf2, and Tgfβ2 in renal cortex of six groups of diabetic mice. (C) PAS staining demonstrating exacerbation of glomerular ﬁbrogenesis after the suppression of miR-200a-3p in
STZ-diabetic mice. Scale bars, 100 μm. (D) Urinary albumin excretion for six groups of STZ-diabetic mice that received either LV-anti-miR-ctrl or LV-anti-miR-200a-3p.
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enzymes will be suppressed, but when AR is inhibited they will be
quickly activated.
At ﬁrst look, the regulation of Keap1, Tgfβ2, and Zeb1/2 by miR-
200-3p’s had been to some degree demonstrated either in cancer
cells or in other kidney cells or tissues. In diabetic kidneys, however,
the expression of miR-200-3p’s was not fully established before our
study. For instance, in diabetic apoE-knockout mice, miR-200a-3p/
141-3p were shown to be signiﬁcantly decreased to promote
ﬁbrogenesis in the kidney tissues [23]. In contrast, Kato et al. [21]
found that miR-200b-3p and miR-200c-3p were increased in the
glomeruli of STZ-diabetic mice and db/db mice. Moreover, although
the roles of miR-200-3p’s in cancer and other diseases were more
clearly demonstrated, few data were available regarding how these
miR-200-3p’s might become dysregulated. In our case, the central
question was how miR-200-3p’s were pathophysiologically regu-
lated in the renal glomeruli. In our current study, we not only
demonstrated that renal cortical miR-200a-3 or miR-141-3p was
signiﬁcantly downregulated in both the STZ-diabetic mice and the
db/db mice, we also showed that these miRNAs appeared to be
regulated by AR. Our demonstration that AR is activated under
hyperglycemia to suppress miR-200-3p’s to coordinate Keap1–Nrf2,
Tgfβ1/2, and Zeb1/2 signaling is of novel importance in part because
it provides a molecular mechanism through which miR-200-3p’s
become dysregulated under diabetic conditions.
Interestingly, Ar itself is transcriptionally regulated by Nrf2 [48] and
miR-200-3p’s are regulated by Tgfβ1 [5]. Moreover, there is more cross
talk between oxidative stress, Tgfβ signaling, ﬁbrogenesis, EMT, and
miR-200-3p signaling [5,10,18,23,32,34,49,50]. Although the interplay
of multiple signaling cascades implicating transcription factors,
miRNAs, cytokines, and other regulatory signals illustrated the com-
plexity of the signaling networks involved in the development of DN,
it is important to distinguish the “leading” or forward cascades versus
the “lagging” or feedback cascades. In this regard, in our opinion Tgfβ1-
mediated transcription of miR-200-3p’s is at most secondary to
hyperglycemia-induced dysregulation in Tgfβ signaling and might
represent a feedback rather than a leading event. Consistent with
this, in this study we showed that overexpression of Ar strongly and/or
acutely repressed the expression of miR-200-3p’s, which are able to
regulate Tgfβ1/2 directly or indirectly. Additionally, in comparisonwith
the appearance of redox imbalance under hyperglycemia, the activa-
tion of Tgfβ is a later event that might itself be triggered by oxidative
stress [32,34]. Assuming that high-glucose-induced alterations in miR-
200-3p’s precede the appearance of overt oxidative stress as well as
the activation of Tgfβ1/2, we propose a simpliﬁed model in an attempt
to emphasize the leading signaling events rather than events that
might represent feedback regulation. In this model (Fig. 8), hypergly-
cemia induces the activation of AR to suppress miR-200a-3p/141-3p.
Relieved from miR-200-3p-mediated gene silencing, Keap1, Tgfβ1/2,
and Zeb1/2 are all activated to repress Nrf2-mediated antioxidant
defense and to promote ﬁbrogenesis and EMT, respectively. Of note is
that AR-induced suppression of miR-200a-3p/141-3p might be con-
comitant with hyperglycemia-induced activation of PKC such that
although Tgfβ1 can be transcriptionally increased by PKC, Tgfβ1/2
mRNAs are stabilized and Tgfβ1/2 protein translation is enhanced
epigenetically through AR-induced repression of miR-200a-3p/141-3p.
When AR is inhibited or deﬁcient, however, the repression of miR-
200a-3p/141-3p by AR is canceled, which leads to the suppression of
Keap1, Tgfβ1/2, and Zeb1/2 signaling such that antioxidant defense is
enhanced, and ﬁbrogenesis and EMT are attenuated. Like killing three
birds with one stone, AR inhibition is expected to upregulate miR-
200a-3p/141-3p to silence Keap1, Tgfβ1/2, and Zeb1/2 to coordinately
control renal oxidative stress, EMT, and ﬁbrogenesis, which might
contribute signiﬁcantly to the ameliorated development of DN as seen
in the Ar-deﬁcient diabetic mice [9].
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